Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Study summary

Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study. Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study. Phase1b of each sub-study will evaluate the safety of the combination and select the dose for the Phase 2 portion. Phase 2 of each sub-study will evaluate the anti-tumor activity of the combination. Sub-Study A is active, not recruiting, ongoing participants are still receiving treatment in Phase 1, Phase 2 will not be initiated. Sub-study B is complete. All participants have discontinued treatment and any additional follow up required by protocol.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedSasanlimab Prefilled syringe and Encorafenib

Plus 4 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jan 9, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?55 U.S. locations

Locations may change over time.

Who runs it?Pfizer

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1 / Phase 2
Sponsor: Pfizer
Interventions being studied: Drug: Sasanlimab Prefilled syringe; Drug: Encorafenib; Drug: Binimetinib; Drug: Sasanlimab; Drug: Axitinib; Drug: SEA-TGT

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Treatment approach

Immunotherapy→Targeted therapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Umbrella Phase 1b \& 2:
Histologically or cytologically confirmed locally advanced/metastatic (Stage IIIB-IV) NSCLC.
At least one measurable lesion per RECIST v1.1 at Screening.
ECOG Performance Status 0 or 1.
Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1.
Adequate hepatic, renal, and bone marrow function. Additional Inclusion Criteria for Sub-Study A Phase 1b \&2: -BRAFV600E mutation in tumor tissue or plasma as determined by a local laboratory PCR or NGS assay and documented in a local pathology report. Additional Inclusion Criteria for Sub-Study A Phase 1b only: -Any line of therapy for locally advanced/metastatic NSCLC. Additional Inclusion Criteria for Sub-Study A Phase 2 only: -Previously untreated for locally advanced/metastatic NSCLC Additional Inclusion Criteria for Sub-Study B Phase 1b only:: -Any line of therapy for locally advanced/metastatic NSCLC. Additional Inclusion Criteria for Sub-Study B Phase 2 only:
Previously untreated for locally advanced/metastatic NSCLC (Arms B1 \& B2), or
One or 2 prior lines of therapy for advanced/metastatic NSCLC (Arm B3), including immune checkpoint inhibitor treatment + chemotherapy, and have progressed during or after that therapy.
PD-L1 TPS ≥1%

Reasons someone may not be able to joinExclusion criteria

Umbrella Phase 1b \&2:
Active or prior autoimmune disease that might deteriorate when receiving an immunostimulatory agent.
Active non-infectious pneumonitis, pulmonary fibrosis, or known history of immune-mediated pneumonitis.
Active infection requiring systemic therapy.
Clinically significant cardiovascular disease.
Other malignancy within 2 years of first dose, with exceptions.
Symptomatic brain metastasis, with exceptions. Additional

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

City of Hope Investigational Drug Services (IDS)Duarte, California
City of HopeDuarte, California
UCSD Medical Center - EncinitasEncinitas, California
California Cancer Associates for Research and Excellence, Inc (cCARE)Fresno, California
The Oncology Institute of Hope and InnovationGlendale, California
Koman Family Outpatient PavilionLa Jolla, California
Sulpizio Cardiovascular Center at UC San Diego HealthLa Jolla, California
UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)La Jolla, California
UC San Diego Moores Cancer Center - Investigational Drug ServicesLa Jolla, California
UCSD Perlman Medical OfficesLa Jolla, California
UC San Diego Moores Cancer CenterLa Jolla, California
The Oncology Institute of Hope and InnovationLong Beach, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 9, 2026. Always confirm current availability with the study team.

View original record ↗